Wearable Devices (WLDS) 6-K 29 Aug 23 Report of Foreign Private Issuer Financial data

Document And Entity Information

Document And Entity Information	6 Months Ended
	Jun. 30, 2023
Document Information Line Items
Entity Registrant Name	WEARABLE DEVICES Ltd.
Document Type	6-K
Current Fiscal Year End Date	--12-31
Amendment Flag	false
Entity Central Index Key	0001887673
Document Period End Date	Jun. 30, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q2
Entity File Number	001-41502

Interim Condensed Consolidated

Interim Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
CURRENT ASSETS:
Cash and cash equivalents	$ 5,954	$ 10,373
Short term bank deposits	2,003
Governmental grant receivable	83	54
Other receivables and prepaid expenses	637	543
Inventories	12	6
TOTAL CURRENT ASSETS	8,689	10,976
NON-CURRENT ASSETS:
Long term bank deposits	52
Right-of-use assets	491	180
Property and equipment, net	137	68
TOTAL NON-CURRENT ASSETS	680	248
TOTAL ASSETS	9,369	11,224
CURRENT LIABILITIES:
Accounts payables	112	156
Advance payments	373	353
Deferred revenues		12
Accrued payroll and other employment related accruals	579	416
Accrued expenses	191	145
Lease liabilities	271	68
TOTAL CURRENT LIABILITIES	1,526	1,150
Lease liabilities	202	94
TOTAL LIABILITIES	1,728	1,244
SHAREHOLDERS’ EQUITY
Ordinary shares, NIS 0.01 par value: Authorized 50,000,000 as of June 30, 2023 and December 31, 2022; issued and outstanding 15,942,984 shares as of June 30, 2023 and 15,049,720 shares as of December 31, 2022	46	43
Additional paid-in capital	24,900	23,346
Accumulated losses	(17,305)	(13,409)
TOTAL SHAREHOLDERS’ EQUITY	7,641	9,980
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$ 9,369	$ 11,224

Interim Condensed Consolidate_2

Interim Condensed Consolidated Balance Sheets (Parentheticals) - ₪ / shares	Jun. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Ordinary shares, par value (in New Shekels per share)	₪ 0.01	₪ 0.01
Ordinary shares, authorized	50,000,000	50,000,000
Ordinary shares, share issued	15,942,984	15,049,720
Ordinary shares, share outstanding	15,942,984	15,049,720

Interim Condensed Consolidate_3

Interim Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands		6 Months Ended
		Jun. 30, 2023	Jun. 30, 2022
Income Statement [Abstract]
Revenues		$ 12	$ 28
Expenses:
Cost of materials		(3)	(5)
Research and development, net		(1,560)	(944)
Sales and marketing expenses		(1,050)	(471)
General and administrative expenses		(1,453)	(587)
Initial public offering expenses			(74)
OPERATING LOSS		(4,054)	(2,053)
FINANCING INCOME, NET		158	2
COMPREHENSIVE AND NET LOSS		$ (3,896)	$ (2,051)
Net loss per ordinary share, basic (in Dollars per share)		$ (0.26)	$ (0.18)
Weighted average number of ordinary shares outstanding basic (in Shares)	[1]	15,254,457	11,136,850
[1]The weighted average number of ordinary shares is excluding the warrants and options described in note 4 below as they are anti-dilutive.

Interim Condensed Consolidate_4

Interim Condensed Consolidated Statements of Comprehensive Loss (Unaudited) (Parentheticals) - $ / shares		6 Months Ended
		Jun. 30, 2023	Jun. 30, 2022
Income Statement [Abstract]
Net loss per ordinary share, diluted		$ (0.26)	$ (0.18)
Weighted average number of ordinary shares outstanding diluted	[1]	15,254,457	11,136,850
[1]The weighted average number of ordinary shares is excluding the warrants and options described in note 4 below as they are anti-dilutive.

Interim Condensed Consolidate_5

Interim Condensed Consolidated Statements of Changes in Shareholders’ Equity (Deficit) (Unaudited) - USD ($) $ in Thousands	Ordinary shares	Additional paid-in capital	Accumulated losses	Total
BALANCE at Dec. 31, 2021	$ 31	$ 7,689	$ (6,913)	$ 807
BALANCE (in Shares) at Dec. 31, 2021	11,136,850
Share based compensation		376		376
Comprehensive loss			(2,051)	(2,051)
BALANCE at Jun. 30, 2022	$ 31	8,065	(8,964)	(868)
BALANCE (in Shares) at Jun. 30, 2022	11,136,850
BALANCE at Dec. 31, 2022	$ 43	23,346	(13,409)	9,980
BALANCE (in Shares) at Dec. 31, 2022	15,049,720
Issuance of shares to April 2021 investors (Note 4a)	$ 1	(1)
Issuance of shares to April 2021 investors (Note 4a) (in Shares)	169,125
Exercise of options	$ 2	1,446		1,448
Exercise of options (in Shares)	724,139
Share based compensation		109		109
Comprehensive loss			(3,896)	(3,896)
BALANCE at Jun. 30, 2023	$ 46	$ 24,900	$ (17,305)	$ 7,641
BALANCE (in Shares) at Jun. 30, 2023	15,942,984

Interim Condensed Consolidate_6

Interim Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (3,896)	$ (2,051)
Adjustments required to reconcile net loss to net cash used in operating activities -
Depreciation	23	11
Share based compensation expenses	109	376
Changes in operating assets and liabilities items:
Increase (decrease) in inventory	(6)	3
Increase in trade receivables		(9)
Increase in deferred initial public offering cost		(25)
Decrease (increase) in governmental grants receivables	(29)	7
Decrease (increase) in other receivables and prepaid expenses	(95)	29
Increase in advance payments	20	11
Decrease in deferred revenues	(12)	(1)
Increase (decrease) in accounts payable	(44)	16
Increase in accrued payroll and other employment related accruals	163	71
Increase in accrued expenses	48	123
Net cash used in operating activities	(3,719)	(1,439)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(93)	(15)
Net change in deposits	(2,055)
Net cash used in investing activities	(2,148)	(15)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of SAFEs (Simple Agreements for Future Equity)		500
Proceeds from issuance of ordinary shares as a result of exercise of warrants	1,448
Net cash provided by financing activities	1,448	500
NET DECREASE IN CASH AND CASH EQUIVALENTS	(4,419)	(954)
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	10,373	1,274
CASH AND CASH EQUIVALENTS AT END OF PERIOD	5,954	320
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Right-of-use asset recognized against lease liability	$ 446	$ 56

General

General	6 Months Ended
	Jun. 30, 2023
General [Abstract]
GENERAL	NOTE 1 – GENERAL a. Wearable Devices Ltd. (the “Company”) was incorporated in Israel in March 2014. The Company develops and sells human-machine interface solutions for the smart wearables industry. The Company is still in its development stage and at an early stage of generating revenues. The Company’s products are designated directly to end users and also designated to businesses in integration of its technology in their smart wearable devices. The Company’s ordinary shares, par value NIS 0.01 per share (“Ordinary Shares”), and warrants began trading on the Nasdaq Capital Market (“Nasdaq”) on September 13, 2022, under the symbols “WLDS” and “WLDSW,” respectively (see Note 4.a below). The Company’s revenues were derived from the sales of Mudra Inspire development kits composed of multiple performance obligations, including tangible parts (hardware) and a limited period (generally one year) application programming interface with no commercial rights, to enable the customer to evaluate the Company’s solution with its own products. b. In 2018, the Company established a wholly owned subsidiary in the United States for the purpose of marketing and distribution of its solutions – Mudra Wearable, Inc. (the “Subsidiary”) – which commenced its operations in 2020. c. The accompanying interim condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. To date, the Company is still at its development stage and at an early stage of generating revenues. Therefore, the Company has suffered recurring losses from operations and negative cash flows from operations since inception. In September 2022, the Company completed an initial public offering (the “IPO”) on Nasdaq and raised net proceeds of $13.3 million. As of June 30, 2023, the Company had incurred accumulated losses of $17.3 million and expects to continue to fund its operations through fundings, such as issuances of convertible securities, Ordinary Shares and warrants and through Israeli governmental grants. There is no assurance that such financing will be obtained. Considering the above, the Company’s dependency on external funding for its operations raises a substantial doubt about the Company’s ability to continue as a going concern. The interim condensed consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.

Basis for Preparation

Basis for Preparation	6 Months Ended
	Jun. 30, 2023
Basis for Preparation [Abstract]
BASIS FOR PREPARATION	NOTE 2 – BASIS FOR PREPARATION The Company’s accompanying condensed consolidated interim financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) for interim financial information. Accordingly, they do not include all of the information and footnote disclosures required by U.S. GAAP for complete financial statements. These condensed interim financial statements should be read in conjunction with the Company’s annual consolidated financial statements and related notes for the year ended December 31, 2022 (the “Annual Financial Statements”). There have been no changes in the Company’s significant accounting policies during the six months ended June 30, 2023, as compared to the critical accounting policies described in note 2 to the Annual Financial Statements. Subsequent events In connection with the preparation of these condensed consolidated interim financial statements, the Company and management evaluated subsequent events through August 23, 2023, the date these condensed consolidated interim financial statements were available to be issued.

Related Parties

Related Parties	6 Months Ended
	Jun. 30, 2023
Related Parties [Abstract]
RELATED PARTIES	NOTE 3 – RELATED PARTIES The employment expenses of the Company’s co-founders who each owns more than 5% of the Company’s Ordinary Shares: Asher Dahan (the Chairman of the Board of Directors and the Chief Executive Officer of the Company), Guy Wagner (President and Director of the Company) and Leeor Langer (the Chief Technology Officer of the Company), for the six months ended June 30, 2023 and 2022 amounted to $174 thousand and $71 thousand, respectively. Starting from September 2022, their monthly salaries were NIS 70 thousand (approximately $19 thousand, plus social benefits and leased car).

Equity

Equity	6 Months Ended
	Jun. 30, 2023
Shareholders’ Equity (Deficit) [Abstract]
Equity	NOTE 4 – EQUITY a. Share capital In September 2022, the Company completed the IPO, in which it issued 3,750,000 Ordinary Shares and warrants to purchase 8,625,000 Ordinary Shares. The warrants have been exercisable immediately upon issuance, at an exercise price of $4.00 per Ordinary Share and are exercisable until September 12, 2027. On September 16, 2022, 40,000 warrants were exercised into 40,000 Ordinary Shares. On December 14, 2022, the exercise price of the warrants was adjusted to $2.00 per Ordinary Share (the “Exercise Price Adjustment”). In June 2023, 724,139 warrants were exercised into 724,139 Ordinary Shares at an exercise price of $2.00 per Ordinary Share. b. Share-based compensation: The table below describes the outstanding warrants to investors and issued warrants as a result of the IPO as of June 30, 2023: Number of Issuance date Exercise price Exercise ratio Expiration date Notes 7,860,861 September 13, 2022 $ 2.00 Each warrant is exercisable into 1 Ordinary Share 5 years following the issuance date Registered for trading 15,760 January to $ 6.35 Each warrant is exercisable into 1 Ordinary Share 18 months from the investment effective date Owned by former SAFEs holders 671,687 September 15, 2022 $ 5.29 Each warrant is exercisable into 1 Ordinary Share 18 months following the issuance date Owned by April 2021 investors 187,500 September 15, 2022 $ 5.31 Each warrant is exercisable into 1 Ordinary Share 5 years following the issuance date Owned by underwriter 23,640 September 15, 2022 $ 4.23 Each warrant is exercisable into 1 Ordinary Share 10 years following the issuance date Owned by the legal advisor The reported sale price of Company’s Ordinary Shares and warrants on Nasdaq was $1.28 and $0.13, respectively, as of August 22, 2023. Options to employees As of June 30, 2023, the Company had 1,053,264 Ordinary Shares available for issuance pursuant to the exercise or vesting of awards under the Company’s 2015 Share Option Plan. Below is a summary of the Company’s option activity and related information with respect to options outstanding at the beginning and end of each period: Number of Weighted-average Outstanding as of January 1, 2023 988,264 $ 0.563 Granted options 65,000 $ 0.643 Outstanding as of June 30, 2023 1,053,264 $ 0.568 Exercisable as of June 30, 2023 825,958 $ 0.641 Following the Company’s Board of Directors approval on December 15, 2022, the Company issued on January 1, 2023, an additional 30,000 options to purchase up to 30,000 Ordinary Shares to certain new employee, with an exercise price of $0.66 per share. On March 21, 2023, the Company’s Board of Directors approved an additional grant of options to purchase up to 35,000 Ordinary Shares to certain new employees, with an exercise price of $0.63 per share. The options will expire at the earlier of (i) ten years from the date of grant or (ii) 90 days following the termination of employment. The fair value of each option as of the grant date was $0.25, determined using the Black-Scholes option pricing model and the total expenses of $9 thousand will be expensed over the option vesting periods of three years. Options to consultants The Company’s outstanding options to consultants as of June 30,2023 were as follows: Issuance date In connection with No. of options issued Exercise price No. of options exercisable 2015 Services rendered 110,655 $ 0.003 110,655 2017 Services rendered 36,885 $ 0.003 36,885 2021 Services rendered 69,090 $ 0.003 - $2.25 69,090 2023 Services rendered 100,000 $ 0.55 - On April 27, 2023, the Company’s Board of Directors approved the additional grant of options to purchase up to 100,000 Ordinary Shares to a consultant, with an exercise price of $0.55 per share. The options will expire at the earlier of (i) ten years from the date of grant or (ii) 90 days following a termination of services. The fair value of each option as of the grant date, was $0.26, determined using the Black-Scholes option pricing model and the total expenses of $26 thousand will be expensed over the option vesting periods of three years.

Significant Events in the Repor

Significant Events in the Reporting Period	6 Months Ended
	Jun. 30, 2023
Significant Events in the Reporting Period [Abstract]
SIGNIFICANT EVENTS IN THE REPORTING PERIOD	NOTE 5 – SIGNIFICANT EVENTS IN THE REPORTING PERIOD a. In January 2023, the Company entered into a new lease agreement for a period which started on February 1, 2023 and will expire on January 31, 2025, with an option to extend the lease period by two additional lease periods, each for an additional 12 months. The Company’s monthly rent payment for this facility is approximately $17 thousand during the first lease year and will be increased to approximately $21 thousand during the second lease year. During the option lease periods, the lease payment may be increased up to 10% as compared to the second lease year. b. In January 2023, the Israeli Innovation Authority (the “IIA”) approved a program to finance further development of the Company’s manufacturing process of its wearable neural interface in Israel. The approved program is in an amount of approximately $900 thousand (NIS 3.1 million), of which the IIA will finance 60%. c. Following note 1f to the Annual Financial Statements, on May 23, 2023, the Company received a notification letter from Nasdaq that the Company had been granted an additional 180-day compliance period, or until November 20, 2023, to regain compliance with Nasdaq’s minimum bid price rule. On June 9, 2023, the Company received a written notice from Nasdaq Stock Market LLC, indicating that it has regained compliance with the minimum bid price requirement.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 6 – SUBSEQUENT EVENTS a. On August 23, 2023, the Company’s Board of Directors approved the allocation and / or grant of additional options to purchase up to 406,500 Ordinary Shares to certain directors, officers and employees, with an exercise price of $1.32 per share. The options will expire at the earlier of (i) ten years from the date of grant or (ii) 90 days following the termination of employment or services. The fair value of each option as of the grant date, was $0.72, determined using the Black-Scholes option pricing model and the total expenses of $293 thousand will be expensed over the option vesting periods of three years. b. On August 23, 2023, the Company’s Board of Directors approved an increase of a total of 931,139 Ordinary Shares underlying options available for grant, for allocation to existing and future employees, consultants and directors of the Company and/or its wholly-owned subsidiary, such that there are currently 3,188,597 Ordinary Shares underlying options granted (including options that were exercised into Ordinary Shares), or reserved for future issuance under the Company’s 2015 Share Option Plan. As of August 23, 2023, the Company had 1,061,637 Ordinary Shares reserved for future issuance under the 2015 Share Option Plan.

Equity (Tables)

Equity (Tables)	6 Months Ended
	Jun. 30, 2023
Shareholders’ Equity (Deficit) [Abstract]
Schedule of Issuance of Equity Warrants to Investors and Associated	The table below describes the outstanding warrants to investors and issued warrants as a result of the IPO as of June 30, 2023: Number of Issuance date Exercise price Exercise ratio Expiration date Notes 7,860,861 September 13, 2022 $ 2.00 Each warrant is exercisable into 1 Ordinary Share 5 years following the issuance date Registered for trading 15,760 January to $ 6.35 Each warrant is exercisable into 1 Ordinary Share 18 months from the investment effective date Owned by former SAFEs holders 671,687 September 15, 2022 $ 5.29 Each warrant is exercisable into 1 Ordinary Share 18 months following the issuance date Owned by April 2021 investors 187,500 September 15, 2022 $ 5.31 Each warrant is exercisable into 1 Ordinary Share 5 years following the issuance date Owned by underwriter 23,640 September 15, 2022 $ 4.23 Each warrant is exercisable into 1 Ordinary Share 10 years following the issuance date Owned by the legal advisor
Schedule of Options Activity	Below is a summary of the Company’s option activity and related information with respect to options outstanding at the beginning and end of each period: Number of Weighted-average Outstanding as of January 1, 2023 988,264 $ 0.563 Granted options 65,000 $ 0.643 Outstanding as of June 30, 2023 1,053,264 $ 0.568 Exercisable as of June 30, 2023 825,958 $ 0.641
Schedule of Options to Consultants	The Company’s outstanding options to consultants as of June 30,2023 were as follows: Issuance date In connection with No. of options issued Exercise price No. of options exercisable 2015 Services rendered 110,655 $ 0.003 110,655 2017 Services rendered 36,885 $ 0.003 36,885 2021 Services rendered 69,090 $ 0.003 - $2.25 69,090 2023 Services rendered 100,000 $ 0.55 -

General (Details)

General (Details) $ in Millions	1 Months Ended
	Sep. 30, 2022 USD ($)	Jun. 30, 2023 USD ($)	Sep. 13, 2022 ₪ / shares
General (Details) [Line Items]
Net proceeds	$ 13.3
Accumulated losses		$ 17.3
Wearable Devices Ltd. [Member]
General (Details) [Line Items]
Ordinary share price (in New Shekels per share) | ₪ / shares			₪ 0.01

Related Parties (Details)

Related Parties (Details) ₪ in Thousands, $ in Thousands	1 Months Ended		6 Months Ended
	Sep. 30, 2022 USD ($)	Sep. 30, 2022 ILS (₪)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)
Related Parties (Details) [Line Items]
Monthly salary (in New Shekels) | ₪		₪ 70
Monthly salary	$ 19
Co-founders [Member]
Related Parties (Details) [Line Items]
Percentage of ownership			5%
Employment expenses			$ 174	$ 71

Equity (Details)

Equity (Details) - USD ($) $ / shares in Units, $ in Thousands			1 Months Ended		6 Months Ended
	Jan. 01, 2023	Sep. 16, 2022	May 21, 2023	Apr. 27, 2023	Jun. 30, 2023	Aug. 22, 2023	Feb. 16, 2023	Dec. 31, 2022	Dec. 14, 2022	Sep. 30, 2022
Shareholders’ Equity (Deficit) (Details) [Line Items]
Ordinary share					15,942,984			15,049,720
Exercise price (in Dollars per share)					$ 4				$ 2
Warrant exercise ,share		40,000			724,139
Ordinary shares issued	30,000	40,000
Ordinary shares.					724,139
Warrants price (in Dollars per share)						$ 0.13
Outstanding - beginning, Amount of options					1,053,264			988,264
Purchase of ordinary shares	30,000
Exercise price per share (in Dollars per share)	$ 0.66
Granted, amount of options			35,000	100,000	65,000
Granted, weighted average exercise price (in Dollars per share)			$ 0.63	$ 0.55	$ 0.643
Termination period			10 years	10 years
Fair value of option grant per share (in Dollars per share)			$ 0.25	$ 0.26
Options expenses (in Dollars)			$ 9	$ 26
Vesting periods			3 years	3 years
Ordinary Shares [Member]
Shareholders’ Equity (Deficit) (Details) [Line Items]
Ordinary share							169,125			3,750,000
Warrants to purchase										8,625,000
Warrant [Member]
Shareholders’ Equity (Deficit) (Details) [Line Items]
Exercise price (in Dollars per share)					$ 2
Subsequent Event [Member]
Shareholders’ Equity (Deficit) (Details) [Line Items]
Share price (in Dollars per share)						$ 1.28

Equity (Details) - Schedule of

Equity (Details) - Schedule of Issuance of Equity Warrants to Investors and Associated	6 Months Ended
	Jun. 30, 2023 $ / shares shares
September 13, 2022 [Member]
Equity (Details) - Schedule of Issuance of Equity Warrants to Investors and Associated [Line Items]
Number of warrants/options | shares	7,860,861
Exercise price | $ / shares	$ 2
Exercise ratio	Each warrant is exercisable into 1 Ordinary Share
Expiration date	5 years following the issuance date
Notes	Registered for trading
January to February 2022 [Member]
Equity (Details) - Schedule of Issuance of Equity Warrants to Investors and Associated [Line Items]
Number of warrants/options | shares	15,760
Exercise price | $ / shares	$ 6.35
Exercise ratio	Each warrant is exercisable into 1 Ordinary Share
Expiration date	18 months from the investment effective date
Notes	Owned by former SAFEs holders
September 15, 2022 one [Member]
Equity (Details) - Schedule of Issuance of Equity Warrants to Investors and Associated [Line Items]
Number of warrants/options | shares	671,687
Exercise price | $ / shares	$ 5.29
Exercise ratio	Each warrant is exercisable into 1 Ordinary Share
Expiration date	18 months following the issuance date
Notes	Owned by April 2021 investors
September 15, 2022 two [Member]
Equity (Details) - Schedule of Issuance of Equity Warrants to Investors and Associated [Line Items]
Number of warrants/options | shares	187,500
Exercise price | $ / shares	$ 5.31
Exercise ratio	Each warrant is exercisable into 1 Ordinary Share
Expiration date	5 years following the issuance date
Notes	Owned by underwriter
September 15, 2022 three [Member]
Equity (Details) - Schedule of Issuance of Equity Warrants to Investors and Associated [Line Items]
Number of warrants/options | shares	23,640
Exercise price | $ / shares	$ 4.23
Exercise ratio	Each warrant is exercisable into 1 Ordinary Share
Expiration date	10 years following the issuance date
Notes	Owned by the legal advisor

Equity (Details) - Schedule o_2

Equity (Details) - Schedule of Options Activity - $ / shares	1 Months Ended		6 Months Ended
	May 21, 2023	Apr. 27, 2023	Jun. 30, 2023
Schedule of Options Activity [Abstract]
Outstanding - beginning, Amount of options			988,264
Outstanding - beginning, Weighted average exercise price			$ 0.563
Granted, Amount of options	35,000	100,000	65,000
Granted, Weighted average exercise price	$ 0.63	$ 0.55	$ 0.643
Outstanding - end, Amount of options			1,053,264
Outstanding - end, Weighted average exercise price			$ 0.568
Exercisable at end, Amount of options			825,958
Exercisable at end, Weighted average exercise price			$ 0.641

Equity (Details) - Schedule o_3

Equity (Details) - Schedule of Options to Consultants	6 Months Ended
	Jun. 30, 2023 $ / shares shares
2015 [Member]
Equity (Details) - Schedule of Options to Consultants [Line Items]
In connection with	Services rendered
No. of options issued	110,655
Exercise price (in Dollars per share) | $ / shares	$ 0.003
No. of options exercisable	110,655
2017 [Member]
Equity (Details) - Schedule of Options to Consultants [Line Items]
In connection with	Services rendered
No. of options issued	36,885
Exercise price (in Dollars per share) | $ / shares	$ 0.003
No. of options exercisable	36,885
2021 [Member]
Equity (Details) - Schedule of Options to Consultants [Line Items]
In connection with	Services rendered
No. of options issued	69,090
No. of options exercisable	69,090
2023 [Member]
Equity (Details) - Schedule of Options to Consultants [Line Items]
In connection with	Services rendered
No. of options issued	100,000
Exercise price (in Dollars per share) | $ / shares	$ 0.55
Minimum [Member] | 2021 [Member]
Equity (Details) - Schedule of Options to Consultants [Line Items]
Exercise price (in Dollars per share) | $ / shares	0.003
Maximum [Member] | 2021 [Member]
Equity (Details) - Schedule of Options to Consultants [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 2.25

Significant Events in the Rep_2

Significant Events in the Reporting Period (Details) $ in Thousands, ₪ in Millions	1 Months Ended
	Jan. 31, 2023 USD ($)	Jan. 31, 2023 ILS (₪)
Shareholders’ Equity (Deficit) (Details) [Line Items]
Lease payment increased	10%
Approved program amount	$ 900	₪ 3.1
IIA finance percentage	60%	60%
First Lease Year [Member]
Shareholders’ Equity (Deficit) (Details) [Line Items]
Rent payment	$ 17
Second Lease Year [Member]
Shareholders’ Equity (Deficit) (Details) [Line Items]
Rent payment	$ 21

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event [Member] $ / shares in Units, $ in Thousands	1 Months Ended
	Aug. 23, 2023 USD ($) $ / shares shares
Subsequent Event [Line Items]
Number of options issued	406,500
Exercise price per share (in Dollars per share) | $ / shares	$ 1.32
Expire term	10 years
Termination of employment or services term	90 days
Fair value of option grant per share (in Dollars per share) (in Dollars per share) | $ / shares	$ 0.72
Total option expenses (in Dollars) | $	$ 293
Vesting periods	3 years
Share Option Plan [Member]
Subsequent Event [Line Items]
Increase in number of options	931,139
Total number of options in plan	3,188,597
Options reserved for future grants	1,061,637